A data-driven, clinical guide to Clomicalm (clomipramine) for canine separation anxiety, detailing TCA vs SSRI mechanisms, safety warnings, and 2,446 FDA reports.

Separation anxiety is one of the most common and challenging behavioral diagnoses in canine veterinary medicine. Characterized by panic-induced behaviors such as vocalization, destructive chew-marks, house-soiling, and hyper-salivation when left alone, it affects an estimated 20% to 40% of dogs referred to veterinary behavior practices in North America. For many owners, the stress of managing a dog with severe separation anxiety leads to caregiver burnout, housing instability, or surrender.

In the United States, pharmacological management of canine behavior is highly regulated. According to the 2015 AAHA Canine and Feline Behavior Management Guidelines, only three behavioral medications are FDA-approved for dogs: clomipramine (Clomicalm) and fluoxetine (Reconcile) for separation anxiety, and selegiline (Anipryl) for canine cognitive dysfunction syndrome (CDS).

Approved under NADA 141-120 (with Clomicalm manufactured by Virbac AH, Inc. and the first generic approved on October 30, 2019), clomipramine is a tricyclic antidepressant (TCA). Although highly effective, clomipramine is often misunderstood. It is not a general sedative, it cannot be used as a standalone cure without concurrent training, and it carries a distinct anticholinergic and hepatic safety profile.

This guide provides a comprehensive, data-anchored analysis of clomipramine for dogs. We review its mechanisms, contrast it head-to-head with the SSRI fluoxetine, analyze 2,446 FDA adverse-event reports, and detail the clinical guidelines, safety contraindications, and adjunct treatment strategies that veterinary professionals and dog owners need to know.

What is Clomipramine (Clomicalm) and How Does it Work?

Clomipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant. In human medicine, it has been used for decades under the brand name Anafranil, primarily to treat obsessive-compulsive disorder (OCD). In veterinary medicine, it was developed specifically as Clomicalm to address the panic states associated with canine separation anxiety.

The Mechanism of Action: Dual-Reuptake Inhibition

To understand how clomipramine alters a dog’s emotional state, we must examine its neurochemical pathway. Unlike newer, highly selective psychotropic drugs, tricyclic antidepressants are "dirty" drugs in the pharmacological sense—they interact with multiple receptor systems, which drives both their therapeutic benefits and their side-effect profile.

The primary therapeutic mechanism of clomipramine involves the inhibition of neurotransmitter reuptake at the synaptic cleft:

Serotonin Reuptake Inhibition: Clomipramine is a potent inhibitor of the serotonin transporter (SERT). By blocking this transporter, it prevents the reabsorption of serotonin into the presynaptic neuron, thereby increasing the concentration of serotonin available to bind to post-synaptic receptors. Serotonin is a key modulator of mood, anxiety, and impulse control.
Norepinephrine Reuptake Inhibition: In the body, clomipramine is metabolized by the liver into its active metabolite, desmethylclomipramine. While the parent drug (clomipramine) is highly selective for serotonin, the active metabolite is a potent inhibitor of the norepinephrine transporter (NET). Norepinephrine is involved in alertness, arousal, and the central response to stress.

By increasing both serotonin and norepinephrine levels, clomipramine helps stabilize the central nervous system's response to acute stressors, such as the owner’s departure.

Secondary Receptor Interactions (The Source of Side Effects)

In addition to reuptake inhibition, clomipramine binds to several other receptors, which accounts for its characteristic side-effect profile:

Muscarinic Cholinergic Receptors (Anticholinergic): Clomipramine acts as an antagonist at muscarinic receptors. This blockade suppresses parasympathetic activity, leading to "dry" signs: decreased salivation, slowed gastrointestinal motility, pupil dilation (mydriasis), and potential urine or stool retention.
Histamine H1 Receptors (Antihistaminic): Antagonism at H1 receptors is responsible for the transient sedation, lethargy, and drowsiness commonly observed when initiating therapy.
Alpha-1 Adrenergic Receptors: Blockade of peripheral α-1 receptors can cause vasodilation and transient orthostatic hypotension (low blood pressure when standing up), which can manifest as mild weakness or wobbliness.

The Core Mandate: Behavior Modification is Not Optional

A critical point emphasized by behaviorists and stated explicitly on the FDA-approved Clomicalm label is that clomipramine is not a standalone treatment and is not a sedative.

The official label indication reads:

"CLOMICALM tablets are to be used as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age."

Why the Medication Needs the Training

Separation anxiety is a panic disorder. Psychotropic medications like clomipramine work by lowering the dog’s baseline anxiety and raising their threshold for panic. This makes the brain receptive to learning.

However, the medication itself does not change the dog's cognitive association with the owner leaving. To achieve long-term resolution, the owner must implement a structured behavior modification program while the dog is on the medication. This typically includes:

Desensitization to Departure Cues: Gradually exposing the dog to actions associated with leaving (picking up keys, putting on a coat, walking toward the door) without actually leaving, until the dog no longer reacts with anxiety.
Counter-Conditioning: Pairing the owner's departure with a highly positive stimulus, such as a long-lasting, food-stuffed toy that is only available when the owner is absent.
Gradual Departures: Starting with absences of only a few seconds and building up to hours, ensuring the dog never crosses the threshold into panic.

If clomipramine is administered without this training, the owner may see a temporary reduction in destructive behavior due to the drug's sedative side effects, but the underlying panic state remains unchanged. When the medication is discontinued, the separation anxiety will return.

The 4-to-8 Week Timeline

Owners must be counseled that clomipramine is a daily, long-acting medication that requires time to accumulate and induce structural changes in the brain (such as receptor downregulation).

Onset: While some mild sedation may be noticed immediately, the true therapeutic, anxiety-reducing effect takes 4 to 8 weeks to become fully apparent.
Expectation Management: Pet owners must not stop the medication after a week because "it isn't working." A minimum trial of 8 weeks is required to evaluate efficacy.

How Clomipramine Compares to Fluoxetine: The TCA vs. SSRI Choice

When choosing a daily behavioral medication for canine separation anxiety, the veterinarian's primary decision is between a tricyclic antidepressant (clomipramine) and a selective serotonin reuptake inhibitor (fluoxetine, sold as Reconcile or Prozac). For the SSRI side of that comparison, see our fluoxetine for dogs guide.

Serotonin vs. Norepinephrine

Fluoxetine (SSRI): Fluoxetine is a highly selective inhibitor of serotonin reuptake. It has virtually no affinity for norepinephrine, histamine, or acetylcholine receptors. This selectivity means fluoxetine has a cleaner profile: it does not cause dry mouth, urinary retention, or marked sedation. It is dosed once daily.
Clomipramine (TCA): Clomipramine acts on both serotonin and norepinephrine, providing a broader neurochemical effect. Because it also blocks histamine and acetylcholine receptors, it carries a higher side-effect load (sedation, dry mouth, GI changes). Because of clomipramine's relatively short half-life in dogs, it is typically dosed twice daily (1 to 2 mg/kg by mouth every 12 hours, for a total daily dose of 2 to 4 mg/kg/day).

Key Clinical Differences

Dosing Frequency: Fluoxetine is once-daily; clomipramine is typically twice-daily. Compliance is often higher with once-daily dosing.
Sedation Profile: Clomipramine has immediate antihistaminic properties, which can help calm a highly agitated dog in the first few days of treatment. Fluoxetine does not have antihistaminic effects; in fact, some dogs experience transient "loading" anxiety or hyper-arousal during the first 2 weeks on fluoxetine.
Appetite Suppression: Both drugs can cause transient appetite loss. However, fluoxetine (Reconcile) is well-documented to cause mild to moderate anorexia in up to 30% of dogs during the initial weeks. Clomipramine is generally better tolerated by dogs that are already prone to selective eating.

Feature	Clomipramine (Clomicalm)	Fluoxetine (Reconcile)
Drug Class	Tricyclic Antidepressant (TCA)	Selective Serotonin Reuptake Inhibitor (SSRI)
Mechanism	Inhibits Serotonin & Norepinephrine reuptake; Anticholinergic; Antihistaminic	Inhibits Serotonin reuptake only
Dosing Frequency	Twice Daily (q12h)	Once Daily (q24h)
Early Sedation	Yes (Common, antihistaminic effect)	No (May cause transient agitation/hyper-arousal)
Anticholinergic Signs	Yes (Dry mouth, constipation, urine retention)	No
Washout Period Required	Yes (Must clear before starting MAOIs or SSRIs)	Yes (Requires a longer washout, up to 14-28 days)

What Do 2,446 FDA Adverse-Event Reports Show?

To establish the real-world safety profile of clomipramine, we analyzed the FDA/CVM openFDA animal adverse-event database using the July 5, 2026 snapshot.

Our analysis identified 2,446 unique adverse-event reports naming clomipramine. The patient species distribution highlights the primary canine target while showing a significant human risk profile:

Dogs: 1,503 reports (61.4% of the dataset)
Humans: 234 reports (reflecting accidental exposures, such as owners mistaking the dog's medication for their own, or children accessing the bottle)
Cats: 121 reports (reflecting off-label veterinary use, primarily for feline urine spraying and psychogenic alopecia)
Other or Unspecified Species: 588 reports — the large majority (~585) are reports in which the species field was not recorded, with a handful of additional cases in birds and other animals

The outcome distribution across the 2,446 reports indicates a manageable safety profile:

Outcome Unknown/Not Provided: 237 reports
Recovered/Normal: 176 reports
Ongoing (still being treated or resolving at the time of the report): 143 reports
Died: 64 reports
Recovered with Sequelae (lasting effect after recovery): 14 reports
Euthanized: 9 reports

Because a single report can list more than one outcome—and many list none—these categories overlap and do not sum to the total report count. The combined death and euthanasia reports (64 Died plus 9 Euthanized = 73, about 3.0% of the dataset) are comparable to other psychotropic medications. Many of these events involved accidental massive ingestions of behavioral medications combined with other household drugs, or older dogs with underlying heart or liver disease that decompensated.

The Reaction Spectrum: The Accidental Exposure and Hepatic Signals

A detailed count of the specific clinical signs reported for clomipramine reveals several key safety warnings:

Clinical Reaction	FDA Report Count	Clinical Significance / Category
Accidental Ingestion / Exposure	406	Toxicology (Overdose)
Depression / Reduced Activity	350	Systemic (Central nervous system)
Vomiting	309	Gastrointestinal
Elevated ALT (Alanine Aminotransferase)	201	Hepatic (Liver enzyme rise)
Anorexia (Appetite Loss)	189	Gastrointestinal / Systemic
Elevated ALP (Alkaline Phosphatase / SAP)	176	Hepatic (Liver enzyme rise)
Lack of Efficacy	162	Therapeutic failure
Diarrhea	139	Gastrointestinal
Aggression (Paradoxical)	113	Behavioral change
Ataxia (Wobbliness)	95	Neurological
Elevated Total Bilirubin	87	Hepatic (Liver)
Nausea	87	Gastrointestinal

Data-quality note: The single most frequent coded entry in the raw clomipramine data is "Tablets, Abnormal" (450 reports), a dispensing/data-quality flag (e.g., broken or wrong tablets) rather than a pharmacologic effect, so it is excluded from the clinical table above.

Three critical insights are visible in this data:

The Accidental Exposure Signal (406 reports): Keep clomipramine strictly out of reach of children and separate from human medications. Because Clomicalm is formulated as a meat-flavored tablet, dogs will actively seek it out, and children may ingest it. In humans, tricyclic antidepressant overdoses are cardiotoxic and represent a life-threatening medical emergency. (Separately, 234 of the 2,446 reports involve a human rather than a dog — reinforcing the household-safety point.)
The Hepatic Enzyme Signal (ALT 201, ALP 176): Although clomipramine is not primarily hepatotoxic, it is metabolized by the liver via cytochrome P450 enzymes. In some dogs, chronic administration can cause subclinical elevations in liver enzymes, requiring routine monitoring.
The Anticholinergic and Neurological Signals: The drug's anticholinergic activity shows up as signs such as dry mouth and dilated pupils (mydriasis) in a smaller subset of reports, while ataxia (95 reports) and a smaller number of seizure/tremor reports highlight a critical drug warning: tricyclics lower the seizure threshold.

Safety Cautions, Warnings, and Contraindications

Due to its broad receptor activity, clomipramine must be used with caution, or avoided entirely, in several patient populations.

Absolute Contraindications

Pre-existing Seizure Disorders: Clomipramine reduces the threshold for electrical seizure activity in the brain. It must never be prescribed to dogs with epilepsy or a history of seizures.
Glaucoma: The anticholinergic effect of clomipramine causes pupillary dilation (mydriasis), which can obstruct the drainage of aqueous humor and trigger an acute, painful spike in intraocular pressure in dogs predisposed to glaucoma.
Heart Disease (Arrhythmias/Heart Block): TCAs are known to prolong the QT interval in cardiac conduction. In dogs with pre-existing arrhythmias, heart block, or congestive heart failure, clomipramine can precipitate fatal cardiac events.
Uretheral Obstruction / Stool Retention: Because anticholinergics decrease smooth muscle contraction in the bladder (detrusor) and gastrointestinal tract, clomipramine will worsen urinary retention or chronic constipation.

Drug-Drug Interactions: The Serotonin Syndrome Gate

Clomipramine must never be administered concurrently with other drugs that increase serotonin levels, as this can lead to serotonin syndrome—a life-threatening condition characterized by mental status changes, muscle tremors, hyperthermia, seizures, and cardiovascular instability.

MAOIs (Monoamine Oxidase Inhibitors): Concurrent use of clomipramine with MAOIs is strictly contraindicated. The primary veterinary MAOI is selegiline (Anipryl) (see our selegiline (Anipryl) for dogs guide). A washout period of at least 14 days is required when switching a dog from selegiline to clomipramine.
Amitraz: Amitraz is an MAOI found in some tick collars (e.g., Preventic) and dips. These collars must be removed before starting clomipramine.
Other Serotonergic Antidepressants: Do not combine clomipramine with fluoxetine (Reconcile) or other SSRIs unless under the direct supervision of a board-certified veterinary behaviorist.
Tramadol: Tramadol is a synthetic opioid frequently prescribed for osteoarthritis pain, but it also acts as a serotonin reuptake inhibitor. Combining tramadol with clomipramine significantly increases the risk of serotonin syndrome.

The Weaning and Withdrawal Plan: Avoid Abrupt Discontinuation

A critical safety rule for clomipramine is: never stop the medication suddenly.

Because the brain adapts to the daily increase in serotonin and norepinephrine by adjusting receptor density, abrupt discontinuation can cause a rapid destabilization of neurochemistry. This manifests as:

Rebound Anxiety: A sudden return of separation anxiety, often in a more severe form than before treatment.
Withdrawal Symptoms: Restlessness, irritability, vocalization, vomiting, and tremors.

How to Wean Safely

When it is time to discontinue clomipramine (usually after the dog has been stable and leak-free for at least 3 to 6 months), the dose must be tapered gradually over several weeks:

Week 1 & 2: Reduce the daily dose by 25% (e.g., if on 2 mg/kg twice daily, reduce to 1.5 mg/kg twice daily).
Week 3 & 4: Reduce the daily dose by 50% (e.g., 1.0 mg/kg twice daily).
Week 5 & 6: Reduce the daily dose to 50% once daily.
Discontinue: Stop administration and monitor the dog's behavior closely for 2 to 4 weeks.

If anxiety signs return during the taper, return to the last effective dose and proceed more slowly.

Adjunct Therapies: Managing Immediate Panic

Because clomipramine takes 4 to 8 weeks to reach therapeutic levels, veterinarians often pair it with faster-acting, situational medications early in treatment.

Trazodone: Trazodone is a serotonin antagonist and reuptake inhibitor (SARI). Unlike clomipramine, which must be given daily, trazodone can be given situationally (1 to 2 hours before the owner leaves). It has a rapid onset of action (providing calming/sedative effects within 2 hours) and has a shorter duration (~4-8 hours). It is frequently used to bridge the gap during the initial weeks of clomipramine therapy. (See our trazodone for dogs guide.)
Gabapentin: Gabapentin is an anticonvulsant and analgesic that acts on voltage-gated calcium channels. It has mild anxiolytic and sedative properties and is safe to use in combination with clomipramine for situational panic. (See our gabapentin for dogs guide.)
Clonidine: Clonidine is an alpha-2 adrenergic agonist. By stimulating presynaptic α-2 receptors, it decreases the release of norepinephrine, reducing the physical manifestations of panic (such as racing heart, panting, and hyper-salivation). It is administered 1 to 2 hours before departures as an add-on to daily clomipramine.

Accidental Overdose and Ingestion Triage

Like other behavioral medications formulated as palatable flavored tablets, Clomicalm carries a significant risk of accidental ingestion. In our analysis of the FDA database, accidental exposure accounted for 406 reports, reflecting cases where dogs gained access to the bottle and consumed multiple tablets.

Toxic Doses and Clinical Signs of TCA Overdose

Tricyclic antidepressants have a narrow margin of safety compared to SSRIs. In dogs, the therapeutic dosage is 2 to 4 mg/kg/day. Toxic thresholds and clinical signs of clomipramine overdose include:

Mild Overdose (2-5× therapeutic dose, ~8-20 mg/kg): Mild to moderate sedation, lethargy, dry mouth, dilated pupils (mydriasis), and mild ataxia (wobbliness).
Moderate Overdose (5-10× therapeutic dose, ~20-40 mg/kg): Marked sedation, severe ataxia, vomiting, salivation or extreme dry mouth, rapid breathing (tachypnea), tachycardia (rapid heart rate), and mild muscle tremors.
Severe/Life-Threatening Overdose (>10× therapeutic dose, >40 mg/kg): Cardiac arrhythmias (including ventricular tachycardia and heart block), severe hypotension or hypertension, seizures, hyperthermia (due to persistent seizure activity), hallucinations, stupor, coma, and potential respiratory or cardiac arrest.

Emergency Intervention Steps

If you suspect your dog has ingested an overdose of Clomicalm:

Calculate the Maximum Ingested Dose: Determine the strength of the tablets (available as 5 mg, 20 mg, and 80 mg) and count the number of missing tablets. Multiply the number of missing tablets by the strength to find the total milligrams ingested, and divide this by your dog's weight in kilograms.
Contact a Professional Immediately: Call your veterinarian, a local emergency veterinary clinic, or an animal poison control center (ASPCA Animal Poison Control Center or Pet Poison Helpline) right away.
Induction of Vomiting: If the ingestion occurred within the last 1 to 2 hours and the dog is completely alert and neurologically normal, your veterinarian may instruct you to induce vomiting using 3% hydrogen peroxide. Do not induce vomiting if the dog is showing signs of sedation, weakness, or tremors, as this can lead to aspiration of vomit into the lungs.
Veterinary Hospitalization and Therapy: Dogs showing moderate to severe signs of clomipramine toxicity require intensive care:
- Decontamination: Administration of activated charcoal with a cathartic to bind the drug and speed its elimination through the GI tract.
- Intravenous Fluids: Hospitalized dogs should receive aggressive IV fluid therapy to support blood pressure and renal perfusion, although fluid diuresis does not accelerate the clearance of clomipramine due to its high protein binding.
- Cardiac Monitoring: Continuous electrocardiogram (ECG) monitoring is critical to detect arrhythmias. Arrhythmias can be treated with anti-arrhythmic agents such as lidocaine or sodium bicarbonate (which helps stabilize cardiac cell membranes in TCA toxicity by altering blood pH).
- Seizure Control: Seizures and severe muscle tremors are managed with intravenous anticonvulsants, primarily diazepam or midazolam. If seizures persist, phenobarbital or propofol infusions may be required.
- Active Cooling: If the dog's body temperature rises dangerously due to tremors or seizures, active cooling measures (tepid water baths, fans) must be initiated.

Frequently Asked Questions

Is Clomicalm a sedative?

No. While some transient drowsiness or lethargy can occur during the first 1 to 2 weeks of starting the drug (due to its antihistaminic effect), Clomicalm is not designed to sedate the dog. Its therapeutic goal is to reduce baseline anxiety and panic, allowing the dog to remain calm and receptive to training while fully awake.

How is clomipramine different from fluoxetine (Reconcile/Prozac)?

Clomipramine is a tricyclic antidepressant (TCA) that affects both serotonin and norepinephrine reuptake and has anticholinergic effects. It is typically dosed twice daily. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that only affects serotonin and has a cleaner side-effect profile. It is dosed once daily.

Can clomipramine be used for cats or for noise phobia?

Yes, it is used off-label in cats, primarily to manage urine spraying and psychogenic grooming. For noise phobias (such as thunderstorms or fireworks), clomipramine is generally not the best choice because it must be given daily; fast-acting, situational medications (like dexmedetomidine oromucosal gel [Sileo] or trazodone) are preferred.

How long does clomipramine take to work for separation anxiety?

It typically takes 4 to 8 weeks of daily administration to see the full therapeutic effect. Owners should not expect immediate behavioral changes and must continue daily training during this period.

Can I stop clomipramine suddenly if my dog has side effects?

No. Stopping clomipramine abruptly can trigger severe rebound anxiety and physical withdrawal signs. If your dog experiences side effects, consult your veterinarian to arrange a safe, gradual weaning plan.

Sources

DailyMed / FDA National Library of Medicine: Clomicalm (clomipramine hydrochloride) Tablets Label (NADA 141-120). Retrieved from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bed54123-2083-465f-97f3-0a796f2a37c7
FDA Center for Veterinary Medicine: FDA Approves Clomipramine Hydrochloride Tablets for Canine Separation Anxiety (October 30, 2019). Retrieved from: https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-clomipramine-hydrochloride-tablets-treat-separation-anxiety-dogs
American Animal Hospital Association (AAHA): 2015 AAHA Canine and Feline Behavior Management Guidelines. Retrieved from: https://www.aaha.org/resources/2015-aaha-canine-and-feline-behavior-management-guidelines/
Veterinary Information Network (VIN) / Veterinary Partner: Clomipramine (Clomicalm) (Calder, DVM, DACVB). Retrieved from: https://veterinarypartner.vin.com/doc?id=4951974&pid=19239
FDA Center for Veterinary Medicine / openFDA: Animal & Veterinary Event API Dataset. Retrieved from: https://api.fda.gov/animalandveterinary/event.json

Vet Med Guide

Clomicalm (Clomipramine) for Dogs: Side Effects & 2,446 FDA Reports